Sparrow Pharmaceuticals
Manufacturing · Oregon, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1050 SW 6th Ave Ste 1100, Portland, Oreg...Phone Number
(617) 465-0328Website
www.sparrowpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for metabolic diseases. Its lead candidate, clofutriben, is an HSD-1 inhibitor designed to reduce intracellular cortisol levels and improve outcomes in patients with hard-to-treat type 2 diabetes and related conditions.Explore more
Sparrow Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sparrow Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Sparrow Pharmaceuticals has new funding data
Earning: See what the market has to say on Sparrow Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Sparrow Pharmaceuticals launches new products
Check if Sparrow Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Sparrow Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sparrow Pharmaceuticals had a recent Job posting/layoffs
Check out if Sparrow Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Sparrow Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Sparrow Pharmaceuticals
Compare insights from companies similar to Sparrow Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sparrow Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sparrow Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sparrow Pharmaceuticals.
Sparrow Pharmaceuticals financials insights
Gather financial insights about Sparrow Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$50M
2025
Private Equity
$61.8M
Series B
$95M
Sparrow Pharmaceuticals Tech Stack
A closer look at the technologies used by Sparrow Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
, according to a recent Form D filing, has secured $61,841,225 in Private Equity funding.
Funding
New Hire
Executive Move
Sparrow Pharmaceuticals News & Media
Sparrow Pharmaceuticals Announces Acceptance of Late-Breaking Presentation of Interim Part 1 Results from CAPTAIN-T2D at the Endocrine Society (ENDO) 2026 Annual Meeting
Sparrow will also present Phase 2 data on cardiometabolic improvements in patients with type 2 diabetes Sparrow will also present Phase 2 data on cardiometabolic improvements in patients with type 2 diabetesSparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients with type 2 diabetes (T2D) at the upcoming Annual American Diabetes Association (ADA) Scientific Session taking place from June 5-8, 2026, in New Orleans, LA.The Escalator: Moderna, Sparrow Pharmaceuticals, Takeda and more
See which leaders are on the move across the pharma, biotech and medical marketing industries.Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sparrow Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for metabolic diseases. Its lead candidate, clofutriben, is an HSD-1 inhibitor designed to reduce intracellular cortisol levels and improve outcomes in patients with hard-to-treat type 2 diabetes and related conditions.... Read More
